Korecyte Bio BV

Korecyte Bio is an international biotech startup based between the Netherlands and United Kingdom that was established in 2023. Our mission is to develop next-generation CAR-T cellular immunotherapies which can safely target a range of solid cancers and deliver improved outcomes for patients with cancer.  

Our team has developed a ground-breaking modular platform technology ‘HypoxiCAR’. We are pioneering new approaches to genetically engineering a patient’s immune cells to identify and attack cancer.

 Our unique approach enables these modified immune cells to lay dormant and circulate in the patient until they sense that they have entered a tumour where they awaken and start vigorously attacking the cancer.

 Korecyte’s HypoxiCAR technology, which can be utilised within any CAR, preserves the killing potential of these cells, and significantly lowers the toxic side effects of these therapies to allow greater numbers of these cells to be given back to a patient. We understand the hardships that cancer patients, and their loved ones, face which is why we are committed to developing the next-generation CAR-T immunotherapy that is safe and effective for treating solid tumours.